Current Report Filing (8-k)
April 29 2022 - 08:01AM
Edgar (US Regulatory)
0001597264
false
0001597264
2022-04-26
2022-04-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 26, 2022
Blueprint Medicines Corporation
(Exact name of registrant as specified in its charter)
Delaware |
|
001-37359 |
|
26-3632015 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
45 Sidney Street
Cambridge, Massachusetts |
|
02139 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (617) 374-7580
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
Common stock, par value $0.001 per share |
BPMC |
Nasdaq Global Select Market |
Item 7.01 Regulation FD.
On April
26, 2022, Charles A. Rowland, Jr. notified Blueprint Medicines Corporation (the “Company”) of his resignation as a Class II
member of the Company’s board of directors (which includes his service on the compensation committee of the board of directors,
and the audit committee of the board of directors, of which he is chair) effective immediately prior to the Company’s 2022 annual
meeting of stockholders. Mr. Rowland’s resignation did not result from any disagreement with the Company on any matter relating
to the Company’s operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BLUEPRINT MEDICINES CORPORATION |
|
|
Date: April 29, 2022 |
By: |
/s/ Kathryn Haviland |
|
|
Kathryn Haviland |
|
|
Chief Executive Officer |
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Mar 2023 to Mar 2024